Latest News

European agency recommends two new adalimumab biosimilars


The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended marketing authorization this week for two new adalimumab biosimilars, Hukyndra and Libmyris.

The biosimilars, both developed by STADA Arzneimittel AG, will be available as a 40-mg solution for injection in a pre-filled syringe and pre-filled pen and 80-mg solution for injection in a pre-filled syringe. Both biosimilars will have 15 indications:

  • rheumatoid arthritis
  • polyarticular juvenile idiopathic arthritis
  • enthesitis-related arthritis
  • ankylosing spondylitis
  • axial spondyloarthritis without radiographic evidence of ankylosing spondylitis
  • psoriatic arthritis
  • chronic plaque psoriasis (adults and children)
  • hidradenitis suppurativa
  • Crohn’s disease (adults and children)
  • ulcerative colitis (adults and children)
  • uveitis (adults and children)

Data show that both Hukyndra and Libmyris are highly similar to the reference product Humira (adalimumab), a monoclonal antibody to tumor necrosis factor alpha, and have comparable quality, safety, and efficacy.

A version of this article first appeared on

Recommended Reading

Higher anti-PC autoantibodies indicate lower risk for cardiovascular events in early RA
MDedge Rheumatology
Risk for herpes zoster in RA higher with tsDMARDs/bDMARDs vs csDMARDs
MDedge Rheumatology
No evidence of increased cancer incidence with long-term TNFi use in RA
MDedge Rheumatology
Fibromyalgianess tied to persistent glucocorticoid use in RA
MDedge Rheumatology
Fostamatinib tied to higher risk for hypertension in RA
MDedge Rheumatology
Can iguratimod be regarded as a potential alternative to methotrexate in RA?
MDedge Rheumatology
Pretreatment resistin levels tied to erosive disease risk in early RA treated with DMARD and infliximab
MDedge Rheumatology
Clinical Edge Journal Scan Commentary: RA September 2021
MDedge Rheumatology
Three JAK inhibitors get boxed warnings, modified indications
MDedge Rheumatology
Low RA flare rate reported after Pfizer COVID vaccination
MDedge Rheumatology